


substituted with one to three substituents independently selected from alkyl, halogen, haloalkyl, alkoxy and haloalkoxy;


m, n, p and q are independently selected from 1 or 2;

R² is selected from the ring systems




T

,




U

,




V

,




X

,




Z

,




AA

,




AB

,




AC

,




AD

,




AE

,




AF

,




AG

,




AH

,



AI

,



AJ


;

R¹¹ is H, alkyl, haloalkyl or cycloalkyl;

R¹² is alkyl, halogen, haloalkyl and alkoxy; R² is selected from the ring systems B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, X, Z, AA, AB, AC, AD, AE, AF, AG, AH, AI and AJ;

5 and pharmaceutically acceptable salts.

In a second aspect, there is provided a process to prepare a compound as defined herein comprising the reaction of a compound of formula (II) in the presence of a compound of formula (III), wherein R^1 , R^2 , A, W, m, n, p and q are as defined above, Y is -OC(O)-.



5 In a third aspect, there is provided a compound as defined herein for use as therapeutically active substance.

In a fourth aspect, there is provided a pharmaceutical composition comprising a compound as defined herein and a therapeutically inert carrier.

10 In a fifth aspect, there is provided a compound as defined herein for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and chronic organ transplant rejection.

In a sixth aspect, there is provided use of a compound as defined herein for the preparation of a medicament for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and
15 chronic organ transplant rejection.

~~In a seventh aspect, there is provided a compound as defined herein, when manufactured according to a process as defined herein.~~

The term “alkenyl” denotes a monovalent linear or branched hydrocarbon group of 2 to 7 carbon atoms with at least one double bond. In particular embodiments, alkenyl has 2 to 4 carbon atoms with at least one double bond. Examples of alkenyl include ethenyl, propenyl, prop-2-enyl, isopropenyl, n-butenyl and iso-butenyl. Particular alkenyl group is ethenyl.
20

The term “alkoxy” denotes a group of the formula -O-R', wherein R' is an alkyl group. Examples of alkoxy group include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy. Particular alkoxy group include methoxy.

W is -O-, -S-, -NR⁶-, -C(O)-, -S(O)₂-, -C(O)-NR⁶- or -CR³R⁴-;


R³ and R⁴ are independently selected from H, halogen, alkyl and cycloalkyl;

R⁵, R⁶ and R⁷ are independently selected from H, alkyl and cycloalkyl;


R⁸, R⁹ and R¹⁰ are independently selected from H, alkyl, hydroxyalkyl, haloalkyl,
5 hydroxyhaloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkoxy, cycloalkoxy,
cycloalkoxyalkyl, cycloalkylalkoxyalkyl, alkoxy, alkoxyalkyl, haloalkoxy,
alkoxyhaloalkyl, alkoxyalkoxy, alkoxyalkoxyalkyl, phenyl, substituted phenyl,
pyridinyl, substituted pyridinyl, pyrrolyl, substituted pyrrolyl, pyrrolydinyl, substituted
pyrrolydinyl, tetrahydrofuranyl, substituted tetrahydrofuranyl, halogen, hydroxy,
10 cyano, alkylsulfanyl, haloalkylsulfanyl, cycloalkylsulfanyl, alkylsulfinyl,
haloalkylsulfinyl, cycloalkylsulfinyl, alkylcarbonyl, haloalkylcarbonyl,
cycloalkylcarbonyl, alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, substituted
aminosulfonyl, substituted amino and substituted aminoalkyl, wherein substituted
aminosulfonyl, substituted amino and substituted aminoalkyl are substituted on the
15 nitrogen atom with one to two substituents independently selected from H, alkyl,
cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, alkylcarbonyl and
cycloalkylcarbonyl, and wherein substituted phenyl, substituted pyrrolyl, substituted
pyrrolydinyl, substituted tetrahydrofuranyl, and substituted pyridinyl are substituted
20 with one to three substituents independently selected from alkyl, halogen, haloalkyl,
alkoxy and haloalkoxy;

m, n, p and q are independently selected from 1 or 2;


R² is selected from the ring systems




T




U




V




X




Z




AA




AB




AC




AD




AE




AF




AG



AH



AI



AJ


R^{11} is H, alkyl, haloalkyl or cycloalkyl;

R^{12} is alkyl, halogen, haloalkyl and alkoxy; R^2 is selected from the ring systems B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, X, Z, AA, AB, AC, AD, AE, AF, AG, AH, AI and AJ;

5 cycloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, substituted aminosulfonyl, substituted amino and substituted aminoalkyl, wherein substituted aminosulfonyl, substituted amino and substituted aminoalkyl are substituted on the nitrogen atom with one to two substituents independently selected from H, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, alkylcarbonyl and cycloalkylcarbonyl, and wherein substituted phenyl and substituted pyridinyl are optionally substituted with one to three substituents independently selected from alkyl, halogen, haloalkyl, alkoxy and haloalkoxy;


m, n, p and q are independently selected from 1 or 2;

10 R² is selected from the ring systems




T

,




U

,




V

,




X

,




Z

,




AA

,




AB

,




AC

,



AD

,



AE


;

R^{11} is H, alkyl, haloalkyl or cycloalkyl;

R^2 is selected from the ring systems B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, X, Z, AA, AB, AC, AD and AE;

5 and pharmaceutically acceptable salts.

3. A compound according to claim 1, wherein R^1 is substituted cycloalkylalkyl, substituted piperazinyl, substituted piperidinyl, substituted indanyloxyalkyl, substituted phenyl, substituted phenylalkyl, substituted phenoxyalkyl, substituted phenylcycloalkyl, substituted phenylalkenyl, substituted pyridinylalkyl, substituted pyridinylalkenyl, naphthyl, substituted naphthyl, substituted quinolinyl, substituted isoquinolinyl, or substituted 1H-



50. A compound according to any one of claims 1 to 48 for use as therapeutically active substance.

5 51. A pharmaceutical composition comprising a compound according to any one of claims 1 to 48 and a therapeutically inert carrier.

52. A compound according to any one of claims 1 to 48 for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and chronic organ transplant rejection.

10 53. The use of a compound according to any one of claims 1 to 48 for the preparation of a medicament for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and chronic organ transplant rejection.

15 ~~54. A compound according to any one of claims 1 to 48, when manufactured according to a process of claim 49.~~